Eli Lilly & Co. told a federal jury that a German company is trying to take credit for centuries-old Chinese medicine in seeking royalties on the use of its erectile-dysfunction drug Cialis to treat an enlarged prostate (Erfindergemeinschaft UroPep GbR v. Eli Lilly & Co., E.D. Tex., 15-1202, trial 4/17/17).
Erfindergemeinschaft UroPep GbR, a company founded by researchers from Hannover Medical School, claims it’s entitled to royalties from Lilly’s sale of Cialis based on a patent for prostate treatment. UroPep is seeking $84.3 million, or 12 percent of the $704 million in Cialis sales since 2011 that relate ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.